Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Risen (Shanghai) Pharma Eng Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being processed by 1 distinct examiner and is located within 1 distinct art unit. Such a centralized prosecution profile suggests that the company's current patent efforts are focused on a specific pharmaceutical innovation. Since the company is only working within 1 distinct art unit, the procedural landscape for their application is relatively straightforward.
Dawanna Shar-Day White is the busiest examiner for this portfolio, managing 1 pending office action. This single action constitutes the total pending workload for the company. With only 1 distinct examiner involved, the outcome of the company's current filing depends entirely on the judgment of this one official. The data shows no other examiners or art units, meaning the company cannot compare this examiner's feedback against other internal benchmarks in the Biotechnology & Pharmaceuticals sector. Consequently, a thorough understanding of this examiner's past decisions is essential for a successful prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18139692 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | WHITE, DAWANNA SHAR-DAY | 55d |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18139692 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | WHITE, DAWANNA SHAR-DAY | 1627 | §112 | Final Rejection | 55d | Pending | Apr 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRisen (Shanghai) Pharma Eng Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dawanna Shar-Day White has the most, with 1 of Risen (Shanghai) Pharma Eng Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.